Hbvaxpro (Aluminium, Hepatitis B Surface Antigen (Rdna) [produced In S. Cerevisiae Cells By Rdna])

Hbvaxpro is indicated for the prevention of hepatitis B virus infection in individuals who have not been previously immunized.

• Primary immunization series for infants, children, and adults.
• Booster dose for persons previously vaccinated whose anti‑HBs levels have declined.
• Use in high‑risk groups such as healthcare workers, dialysis patients, and individuals with chronic liver disease.
• Administration before potential exposure to hepatitis B, including travel to endemic regions.
• Inclusion in combination vaccination schedules when hepatitis B protection is required alongside other pediatric vaccines.
• Vaccination of pregnant women at risk of hepatitis B exposure, following local clinical guidelines.

The safety profile of Hbvaxpro reflects that of other recombinant hepatitis B vaccines; most adverse events are mild, self‑limiting, and resolve without medical intervention.

Common

• Pain, redness, or swelling at the injection site.
• Low‑grade fever.
• Fatigue or mild headache.
• Nausea or mild gastrointestinal discomfort.
• Mild muscle aches or arthralgia.
• Transient dizziness.

Serious

• Allergic reactions such as urticaria, angioedema, or anaphylaxis.
• Neurological events including Guillain‑Barré syndrome (rare).
• Severe local reaction with extensive necrosis (very rare).
• Autoimmune phenomena such as systemic lupus erythematosus flare (extremely rare).
• Severe hypotension or shock unrelated to anaphylaxis (extremely rare).

Before administering Hbvaxpro, healthcare providers should assess individual risk factors and follow standard vaccination precautions.

• Do not vaccinate individuals with a known severe allergy to any component, including aluminium salts.
• Postpone vaccination in persons experiencing moderate or severe acute illness.
• Observe the patient for at least 15 minutes after injection to detect immediate hypersensitivity.
• Use caution in pregnant or lactating women; weigh potential benefits against unknown risks.
• Evaluate immune status; immunocompromised patients may have a reduced antibody response.
• Ensure proper storage and handling according to the manufacturer’s temperature requirements.
• Record any previous hepatitis B vaccination history to determine need for booster dosing.

Hbvaxpro does not have extensive documented drug‑drug interactions, but certain concomitant therapies may influence vaccine response or safety.

Avoid

• Concurrent administration of other injectable vaccines at the same anatomical site.
• Use of systemic corticosteroids or immunosuppressants at high doses that could blunt antibody formation.

Use with caution

• Antipyretics (e.g., acetaminophen, ibuprofen) taken prophylactically may reduce immunogenicity; use only if needed for symptom relief.
• Live attenuated vaccines given within four weeks before or after Hbvaxpro, to avoid interference with immune response.
• Blood products or immunoglobulins administered within 3 months, which may affect seroconversion rates.